News coverage about Akari Therapeutics PLC (NASDAQ:AKTX) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akari Therapeutics PLC earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.8955427816138 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Akari Therapeutics PLC (AKTX) traded up 5.12% during mid-day trading on Friday, reaching $4.31. The company had a trading volume of 520,942 shares. The stock’s market capitalization is $50.75 million. The firm has a 50 day moving average of $5.83 and a 200-day moving average of $6.72. Akari Therapeutics PLC has a one year low of $3.18 and a one year high of $22.20.
A number of research analysts have recently commented on the company. Zacks Investment Research cut Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics PLC in a research report on Sunday, September 17th. William Blair reaffirmed an “outperform” rating on shares of Akari Therapeutics PLC in a research report on Tuesday, July 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Akari Therapeutics PLC in a research report on Friday, September 22nd. Finally, ValuEngine raised Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $8.00.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/akari-therapeutics-plc-aktx-receives-news-sentiment-score-of-0-12.html.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.